Introduction and purpose
Methods
Literature search
Statistical analysis
Definition and classification
Statements/recommendations:
-
Agenesis: absence of one kidney suspected on US scan between the 18th and 22nd weeks of gestation and confirmed postnatally.
-
Aplasia: a rudimentary kidney suspected on US scan between the 18th and 22nd weeks of gestation, with relative function < 5% at 99mTc-dimercaptosuccinic acid scintigraphy (DMSA).
-
MCDK: multiple non-communicating cysts of various sizes within a lobulated renal contour, pelvis and parenchyma not being visible on US.
-
Undefined CSK: detection of an empty kidney fossa in the third trimester of pregnancy or after birth, with the differential diagnosis of agenesis, aplasia, or an involuted MCDK remaining uncertain (grade C).
What to do when a CSK is suspected/diagnosed by ultrasound prenatally?
Statements/recommendations:
How should a CSK be confirmed postnatally?
Statements/recommendations:
What further imaging is required when a CSK is confirmed?
-
a. Is the CSK normal at US?
-
b. Should imaging to detect VUR be performed routinely?
-
c. When should further imaging for associated uropathies be performed?
a) Is the CSK a normal kidney?
US parameter | Needed description | Normal findings | Timing |
---|---|---|---|
Kidney length | Bipolar diameter in millimeters | > 50th percentile ≥ 95th percentile | Until 2 years of life After 2 years of life |
Parenchyma | Thickness Echogenicity Cortico-medullary differentiation Cysts | Normal Normal Normal Absent | Any time |
Renal pelvis | Antero-posterior diameter in millimeters | ≤ 10 mm | > 48 h of life |
Calices | Dilatation | Absent | Any time |
Ureter | Dilatation | Absent | Any time |
Bladder | Wall thickness Ureterocele | Normal Absent | Any time |
Statements/recommendations:
b) Should imaging to detect VUR be performed routinely?
Author, year | Number of pts | CSK type (%) | Associated CAKUT, % | Total VUR, % | VUR grades III–V, % | UPJO, % | VUJO, % |
---|---|---|---|---|---|---|---|
3557 | MCDK (100) | 31.3 (of 2415 pts) | 15 (of 2104 pts) | 8 | 4.8 (of 2159 pts) | NR | |
1093 | UKA (100) | 32 | 24 (of 770 pts) | NR | 6 (of 615 pts) | 7 (of 605 pts) | |
La Scola C. (2016) [7] | 146 | MCDK (38), UKA (29), UKAP (16), Undefined (18) | 21 | 11.5 | 10 | 2 | 3 |
Ross I. (2015) [42] | 138 | MCDK (63), UKA (37) | NR | 36 | 17 | NR | NR |
Marzuillo P. (2017)[31] | 322 | MCDK (48), UKA (52) | 14.6 | 9.3 | 5.6 | 0.3 | 4 |
Brown C. (2019) [43] | 165 | MCDK (100) | 33 | 17 (of 77 pts) | NR | NR | NR |
Blachman-Braun R. (2020) [41] | 156 | MCDK (100) | NR | 16 | 6 | NR | NR |
Statements/recommendations:
c) When should further imaging for associated uropathies be performed?
Statements/recommendations:
Are laboratory tests necessary at diagnosis?
Statements/recommendations:
When and how should extra-renal malformations be searched for?
Number of pts | Genital | Cardiac | Musculo-skeletal | Inguinal hernia | Haemato-poietic | Eye | Nervous | Endocrine | Gastro-intestinal | Respiratory | Syndromes | Total*** | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1340 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 14.9% | |
Mansoor O. (2011) [34] | 101 | - | 3% | - | - | - | - | - | - | - | - | 3% | 6% |
709 | 11%** | 14% | 13% | NR | NR | NR | NR | NR | 16% | NR | NR | 31% | |
La Scola C. (2016) [7] | 146 | 9% | 7.5% | 7.5% | 2% | 1.4% | - | 6.1% | 5.5% | 3.4% | 1.4% | 10.3% | 26% |
Groen in’t Wood S. (2016) [50] | 49 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 12.2% |
Marzuillo P. (2017) [31] | 322 | 3.4% | 3.1% | 0.3% | 1.2% | 0.6% | 0.6% | - | - | - | - | 1.2% | 10.5% |
Syndrome | Extrarenal manifestations | Genes | Possible inheritance |
---|---|---|---|
Branchio-oto-renal | Sensorineural hearing loss, preauricular pits, branchial cysts, and microtia | EYA1, SIX1, SIX5 | Autosomal dominant |
DiGeorge | Congenital heart disease, hypocalcaemia, immunodeficiency, and neurocognitive disorders | 22q11 deletion | Autosomal dominant |
Fraser | Cryptophthalmos, cutaneous syndactyly, occasionally malformations of the larynx, ambiguous genitalia, and mental retardation | FRAS1, FREM2 | Autosomal recessive |
Herlyn-Werner-Wunderlich or OHVIRA (obstructed hemivagina and ipsilateral renal agenesis) | Obstructed hemivagina and uterus didelphys | Unknown | Autosomal dominant |
Kallmann 1 | Micropenis, bilateral cryptorchidism, and anosmia | KAL1 | X-linked |
Klinefelter | Small, firm testis, gynaecomastia, azoospermia, and hypergonadotropic hypogonadism | 47, XXY | Sporadic |
MURCS (Mayer-Rokitansky-Kuster–Hauser type 2) | Müllerian duct aplasia-hypoplasia and cervicothoracic somite dysplasia | Unknown | Autosomal dominant |
Renal coloboma | Retinal and optic nerve coloboma | PAX2 | Autosomal dominant |
Renal cysts and diabetes | Maturity-onset diabetes of the young type 5, hyperuricaemia, hypomagnesemia, and uterine malformations | HNF1B | Autosomal dominant |
Townes–Brocks | Thumb anomalies, imperforate anus, and sensorineural hearing loss | SALL1 | Autosomal dominant |
VACTERL association | Vertebral anomalies, anorectal malformations, cardiovascular disease, tracheoesophageal fistula, esophageal atresia, and limb defects | TRAP1 | Autosomal recessive |
Williams–Beuren | Developmental delay, cardiovascular anomalies, mental retardation, and facial dysmorphology | 7q11.23 deletion | Autosomal dominant |
Statements/recommendations:
Is it necessary to perform genetic analysis in non-syndromic forms of CSK?
Statements/recommendations:
Risk of decreasing glomerular filtration rate and of kidney damage (proteinuria and hypertension) over time
a) Is a child with CSK at risk of decreasing glomerular filtration rate?
Author, year | Age | N | Compensatory enlargement* | Ipsilateral CAKUT | Kidney injury | GFR reduction | Proteinuria/albuminuria | Hypertension | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Definition | Outcome N (%) | Evaluated as | Outcome N (%) | Evaluated as | Outcome N (%) | Definition | Outcome N (%) | |||||
Weinstein A. (2008) [22] | C | 80 | 80% | NR | eGFR < 90 ml/min/1.73 m2 | 0/23 | Dipstick > + 1 | 0/20 | > 95th pct | 0/31 (0) | ||
Vu K. H. (2008) [4] | C | 56 | "normal kidneys" | None | eGFR < 90 ml/min/1.73 m2 | 6/56 (10.7) | ACR > 0.25 mg/mg | 4/52 (7.7) | > 95th pct | 3/56 (5.3) | ||
Abou Jaoudé P. (2011) [62] | C | 44 | "normal kidneys" | None | mGFR < 90 ml/min/1.73 m2 | 5/44 (11.4%) | UAlb/UCr > 2 mg/mmol | 8/44 (18) | > 95th pct | 1/44 (2.2) | ||
Mansoor O. (2011)[34] | C | 121 | 74% | 25% (of 101 patients) | eGFR < 90 ml/min/1.73 m2 | 8/82 (9.7) | UPr/UCr ≥ 0.2 mg/mg | 14/82 (17) | > 95th pct | 6/86 (7) | ||
Hayes W. N. (2012) [30] | C | 323 | 97% | 14% | mGFR < 90 ml/min/1.73 m2 | 33/76 (43) | NR | 0/94 (0) | ||||
Stefanowicz J. (2012) [63] | C | 17 | NR | None | eGFR < 90 ml/min/1.73 m2 | 0/17 | ACR > 30 mg/g | 4/17 (24) | > 95th pct | 1/17 (6) | ||
Westland R. (2013) [64]** | C | 223 | NR | 26% | Hy and/or Proteinuria and/or eGFR < 60 ml/min/1.73 m2 and/or RPM | 68/223 (31) | eGFR < 60 ml/min/1.73 m2 | 9/223 (4) | UPr/UCr > 0.2 mg/mg (> 0.5 if < 2 yrs) or ACR > 30 mg/g | 29/223 (13) | > 95th pct | 49/223 (22) |
Kolvek G. (2014) [65] | C | 27 | NR | 29% | Hy and/or Proteinuria and/or eGFR < 60 ml/min/1.73 m2, and/or RPM | 9/27 (33.3) | eGFR < 60 ml/min/1.73 m2 | 3/27 (11) | ≥ 300 mg/24 h | 2/27 (7.4) | > 95th pct | 5/27 (18) |
Siomou E. (2014) [66] | C | 38 | 100% | 0 | eGFR < 90 ml/min/1.73 m2 | 17/38 (44.7) | > 95th pct | 4/38 (11) | ||||
La Scola C. (2016) [7] | C | 146 | 65% | 21% | eGFR < 90 ml/min/1.73 m2 | 18/146 (12) | UPr/UC > 0.2 mg/mg (> 0.5 if < 2 yrs) | 5/134 (4) | > 95th pct | 6/121 (5) | ||
Marzuillo P. (2017) [31]*** | C | 322 | 74% | 15% | Hy or Proteinuria or eGFR < 90 ml/min/1.73 m2 | 12/306 (3.9) | eGFR < 90 ml/min/1.73 m2 | 4/306 (1.3) | UPr/UC > 0.2 mg/mg (> 0.5 if < 2 yrs) | 11/306 (3.6) | > 95th pct | 2/306 (0.6) |
Urisarri A. (2018) [17] | C | 128 | 64% | 35% | eGFR < 60 ml/min/1.73 m2 | 3/128 (2.3) | ACR 30 mg/g | 4/128 (3) | > 95th pct | 6/128 (4.6) | ||
Poggiali I. (2019) [48] | C | 162 | NR | 26% | Hy, Proteinuria and eGFR < 60 ml/min/1.73 m2 | 18/162 (11.1) | eGFR < 60 ml/min/1.73 m2 | 9/162 (5.6) | UPr/UCr > 0.2 mg/mg or > 150 mg/day | 10/162 (6.2) | > 95th pct | 11/162 (6.8) |
Sanna Cherchi S. (2009) [68] | A | 111 | NR | NR | eGFR < 15 ml/min/1.73 m2 | 23/111 (21) | > 1 g/day | 5/111 (4.5) | NR | 3/111 (2.7) | ||
Argueso L. R. (1992) [67] | A | 157 | 100% | NR | mGFR < 90 ml/min/1.73 m2 | 4/32 (13) | > 150 mg | 7/37 (19) | > 160/95 mmHg and/or T | 22/47 (47) | ||
Wang Y. (2010) [38] | A | 65 | NR | NR | mGFR < 60 ml/min/1.73 m2 | 25/65 (38) | ACR > 10 mg/mmol or RPM | 31/65 (48) | > 140/90 mmHg and/or T | 24/65 (36) | ||
Basturk T. (2015) [39] | A | 31 | NR | NR | sCr > 1.4 mg/dl in men or > 1.3 mg/dl in women or eGFR < 60 ml/min/1.73 m2 or Proteinuria ≥ 300 mg/day | 17/31 (55) | mGFR < 60 ml/min/1.73 m2 | 14/31 (45) | UPr ≥ 300 mg/day | 12/31 (39) | NR | 21/31 (67) |
Xu Q. (2019) [69] | A | 118 | NR | NR | Hy, Proteinuria and eGFR < 60 ml/min/1.73 m2 | 62/118 (53) | eGFR < 60 ml/min/1.73 m2 | 30/118 (25.4) | > 150 mg/day | 49/114 (43) | ≥ 140/90 mmHg | 38/118 (32.2) |
Outcome | Population | N. of cohorts | Mean ± sd | Median (IQR) |
---|---|---|---|---|
GFR reduction | 13 | 8.7 ± 12.3% | 5.6% (8.8%) | |
GFR reduction < 90 ml/min/1.73 m2 | 9 | 11.5 ± 15.9% | 10.7% (11.0%) | |
GFR reduction < 60 ml/min/1.73 m2 | 4 | 4.4 ± 2.3% | 4.8% (2.9%) | |
GFR reduction | 5 | 26.9 ± 10.6% | 25.4% (17.7%) | |
Proteinuria/albuminuria | 11 | 7.6 ± 5.8% | 6.2% (9.4%) | |
5 | 29.0 ± 21.0% | 43.0% (24.0%) | ||
Hypertension | 13 | 7.1 ± 8.1% | 5.0% (6.3%) | |
5 | 29.0 ± 22.6% | 32.2% (14.6%) | ||
ABPM hypertension | 8 | 28.0 ± 9.7% | 31.1% (13.0%) | |
ABPM masked hypertension | 6 | 14.3 ± 11.9% | 19.9% (19.4%) |
Risk factors | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author, year | Age | Outcome | Absence of compensatory enlargement | CAKUT (ipsilateral) | UTI | Baseline creatinine | Baseline eGFR | Proteinuria | Hypertension | Hematuria | Age | Family History of CAKUT | Low Birth weight | Birth length | Prenatal diagnosis | Body mass index | Diabetes Mellitus | Uric Acid | RAS blockade | Duration of follow-up | Extrarenal anomalies | Gender | Phenotype | Prematurity | Side |
C | eGFR < 90 ml/min/1.73 m2 8/82 (9.7%) | + | |||||||||||||||||||||||
C | KI 68/223 (31%) | + + | + + | + | + + | + | + | ns | ns | ns | |||||||||||||||
C | KI 9/27 (33.3%) | + | |||||||||||||||||||||||
eGFR < 60 ml/min/1.73 m2 3/27 (11.1%) | + | ||||||||||||||||||||||||
La Scola (2016) [7] | C | eGFR < 90 ml/min/1.73 m2 18/146 (12%) | + + | + | + | ns | ns | ns | ns | ns | |||||||||||||||
C | KI 12/306 (3.9%) | ns | + + | ns | ns | ns | ns | ||||||||||||||||||
Urisarri (2018) [17] | C | eGFR < 60 ml/min/1.73 m2 3/128 (2.3%) | ns | + | ns | ns | ns | ns | |||||||||||||||||
Poggiali (2019) [48] | C | KI 18/162 (11.1%) | + + | + | + + | + + | + | + | ns | ns | ns | ns | ns | ||||||||||||
eGFR < 60 ml/min/1.73 m2 9/162 (5.6%) | ns | + | + | + | + | ns | + | ns | ns | ns | ns | ||||||||||||||
Wang (2010) [38] | A | mGFR < 60 ml/min/1.73 m2 25/65 (38%) | + + | + + | ns | ns | ns | ns | ns | ||||||||||||||||
Basturk (2015) [39] | A | eGFR < 60 ml/min/1.73 m2 14/31 (45%) | ns | ns | ns | + | + | ns | ns | + | + | ns | ns | ns | |||||||||||
Xu (2019) [69] | A | eGFR < 60 ml/min/1.73 m2 30/118 (25.4%) | + | + | + | + | ns | ns | ns | + | ns | ns | ns | ||||||||||||
eGFR < 30 ml/min/1.73 m2 Prevalence NR | ns | + + | ns | ns | ns | ns |
Statements/recommendations:
b) Is a child with CSK at risk of proteinuria?
Statements/recommendations:
c) Is a child with CSK at risk of developing hypertension?
Statements/Recommendations:
Should ambulatory blood pressure monitoring be performed in children with CSK?
Author, year | N | Age at ABPM (yrs) | Compensatory enlargement* | Ipsilateral CAKUT | eGFR < 90 ml/min/1.73 m2 | OBP hypertension | ABPM hypertension | Masked hypertension | WCH | Abnormal dipping |
---|---|---|---|---|---|---|---|---|---|---|
Seeman T. (2001) [70] | 25 | 7.8 (3.8–17.7) | 21/25 (84%) | 4/25 (16%) | 2/25 Mean eGFR 55, 23/25 Mean eGFR 110, range 85–159 | 8/25 (33%) | 5/25 (20%) | 1/25 (4%) | 4/25 (16%) | 5/25 (20%) |
Mei-Zahav M. (2001) [85] | 18 | 9.6 ± 3.9 | 18/18 (100%) | 0/18 | 0/18 | NR | NR | NR | NR | 0/18 |
Seeman T. (2006) [28] | 15 | 10.0 (4–17) | 13/15 (87%) | 0/15 | 0/15 | 5/15 (33%) | 1/15 (7%) | 0/15 | 4/15 (26%) | 2/15 (14%) |
Dursun H. (2007) [71] | 44 | 8.3 ± 4.2 | NR | 0/44 | 0/44 | NR | 10/44 (23%) | NR | NR | 13/44 (29.5%) |
Westland R. (2014) [72] | 28 | 12.5 ± 3.6 | 24/28 (86%) | NR | 0/28 | 2/28 (7%) | 7/28 (25%) | 5/28 (18%) | 0/28 | 8/28 (29%) |
Tabel Y. (2015) [73] | 44 | 10.9 ± 3.3 | NR | NR | 0/44 | NR | 19/44 (43%) | NR | NR | NR |
Lubrano R. (2017) [74] | 38 | About 14.5 | NR | Scars 24/38 (63%) | Mean eGFR 103.76 ± 46.49 | 11/38 (29%) | 11/38 (29%) | 0/38 | 0/38 | NR |
Zambaiti E. (2018) [32] | 50 | 9.5 ± 4.2 | 39/50 (78.5%) | NR | Mean eGFR 80.6 ± 12.2 | 10/50 (20%)** | 23/50 (46%)*** | NR | NR | 41/50 (82%) |
La Scola C. (2020) [37] | 81 | 11.8 ± 4.7 | NR | 9/50 (18%) | 0/81 | 13/81 (16%) | 27/81 (33.3%) | 21/81 (25.9%) | 7/81 (8.6%) | 51/81 (64%) |
Kasap-Demir B. (2021)[75] | 36 | 11 ± 4.75 | NR | 0/36 | 1/36 (3%) Mean eGFR 127.3 ± 19.85 | 10/36 (28%) | 7/36 (19%) | 5/36 (14%) | 8/36 (22%) | NR |
Statements/recommendations:
Can kidney protective medication be used safely in CSK?
Statements/recommendations:
Which nutritional and lifestyle habits should be adopted for children with a CSK?
Statements/recommendations:
Can sports be played without restraint by subjects with a CSK?
Statements/recommendations:
What follow-up for children with a CSK?
Low risk* | Medium risk* | High risk* | ||
---|---|---|---|---|
Without CAKUT | With ipsilateral CAKUT | |||
Setting | Primary pediatric care1 | Pediatric nephrologist1/pediatric nephrology unit | Pediatric nephrology unit | |
Ultrasound2 | Yearly until 3 years of age, then every 5 years | Yearly until 3 years of age, then every 3 to 5 years | Further work-up depending on additional ipsilateral CAKUT findings | According to kidney function and clinical data |
Proteinuria by urinalysis3 | Yearly until 3 years of age, then every 5 years | Yearly | ||
Office Blood pressure | Yearly ≥ 3 years | Yearly | ||
Serum creatinine/eGFR | Not necessary | Yearly | ||
Abdominopelvic ultrasound in girls | Between thelarche and menarche | Between thelarche and menarche | Between thelarche and menarche |
Statements/recommendations:
Health benefits, limitations of our recommendations and future perspectives
-
first, US growth nomograms specific for CSK on large cohorts are lacking and should be elaborated;
-
second, further studies are needed to validate a risk stratification model applicable early in life, to tailor follow-up accordingly;
-
third, the presence, degree, and time course of hyperfiltration in human CSK and its influence on subsequent kidney injury should be studied.